In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung. / Roed, H; Aabo, K; Vindeløv, L; Spang-Thomsen, M; Christensen, I B; Hansen, H H.

I: European journal of cancer & clinical oncology, Bind 25, Nr. 8, 1989, s. 1197-201.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Roed, H, Aabo, K, Vindeløv, L, Spang-Thomsen, M, Christensen, IB & Hansen, HH 1989, 'In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung', European journal of cancer & clinical oncology, bind 25, nr. 8, s. 1197-201.

APA

Roed, H., Aabo, K., Vindeløv, L., Spang-Thomsen, M., Christensen, I. B., & Hansen, H. H. (1989). In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung. European journal of cancer & clinical oncology, 25(8), 1197-201.

Vancouver

Roed H, Aabo K, Vindeløv L, Spang-Thomsen M, Christensen IB, Hansen HH. In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung. European journal of cancer & clinical oncology. 1989;25(8):1197-201.

Author

Roed, H ; Aabo, K ; Vindeløv, L ; Spang-Thomsen, M ; Christensen, I B ; Hansen, H H. / In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung. I: European journal of cancer & clinical oncology. 1989 ; Bind 25, Nr. 8. s. 1197-201.

Bibtex

@article{45c60280654f11de8bc9000ea68e967b,
title = "In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung",
abstract = "As the indoloquinone EO-9 has previously shown activity in several tumor model systems it was evaluated against four human small cell lung cancer cell lines by the clonogenic assay. In two cell lines (Nyh and Tol), exponential dose-response curves were achieved with both 1 h and continuous exposure, whereas no cell kill was obtained in the other two cell lines (69 and 592) when tested with 1 h incubation up to 0.25 microgram/ml. When the cells were exposed to drug in vitro, flow cytometric DNA analysis showed perturbations in the cell cycle distribution of the most sensitive cell line (Tol) at a lower EO-9 concentration than in the less sensitive cel line (592). This in vitro predicted difference in EO-9 sensitivity between two of the cell lines (592 and Tol) was confirmed when the cell lines were heterotransplanted to nude mice.",
author = "H Roed and K Aabo and L Vindel{\o}v and M Spang-Thomsen and Christensen, {I B} and Hansen, {H H}",
note = "Keywords: Animals; Antineoplastic Agents; Aziridines; Carcinoma, Small Cell; Cell Line; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Humans; Indolequinones; Indoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Quinones; Tumor Stem Cell Assay",
year = "1989",
language = "English",
volume = "25",
pages = "1197--201",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "8",

}

RIS

TY - JOUR

T1 - In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung

AU - Roed, H

AU - Aabo, K

AU - Vindeløv, L

AU - Spang-Thomsen, M

AU - Christensen, I B

AU - Hansen, H H

N1 - Keywords: Animals; Antineoplastic Agents; Aziridines; Carcinoma, Small Cell; Cell Line; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Humans; Indolequinones; Indoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Quinones; Tumor Stem Cell Assay

PY - 1989

Y1 - 1989

N2 - As the indoloquinone EO-9 has previously shown activity in several tumor model systems it was evaluated against four human small cell lung cancer cell lines by the clonogenic assay. In two cell lines (Nyh and Tol), exponential dose-response curves were achieved with both 1 h and continuous exposure, whereas no cell kill was obtained in the other two cell lines (69 and 592) when tested with 1 h incubation up to 0.25 microgram/ml. When the cells were exposed to drug in vitro, flow cytometric DNA analysis showed perturbations in the cell cycle distribution of the most sensitive cell line (Tol) at a lower EO-9 concentration than in the less sensitive cel line (592). This in vitro predicted difference in EO-9 sensitivity between two of the cell lines (592 and Tol) was confirmed when the cell lines were heterotransplanted to nude mice.

AB - As the indoloquinone EO-9 has previously shown activity in several tumor model systems it was evaluated against four human small cell lung cancer cell lines by the clonogenic assay. In two cell lines (Nyh and Tol), exponential dose-response curves were achieved with both 1 h and continuous exposure, whereas no cell kill was obtained in the other two cell lines (69 and 592) when tested with 1 h incubation up to 0.25 microgram/ml. When the cells were exposed to drug in vitro, flow cytometric DNA analysis showed perturbations in the cell cycle distribution of the most sensitive cell line (Tol) at a lower EO-9 concentration than in the less sensitive cel line (592). This in vitro predicted difference in EO-9 sensitivity between two of the cell lines (592 and Tol) was confirmed when the cell lines were heterotransplanted to nude mice.

M3 - Journal article

C2 - 2548870

VL - 25

SP - 1197

EP - 1201

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 8

ER -

ID: 12870988